Perjeta 420 MG/14 ML vial 14ML
Ended Awarded
- Contract number
- SPE2DB25FPRR5
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $18,229
Award facts
- Contract value 100% obligated
- $18,229.08 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order by the Defense Logistics Agency (DLA) on September 26, 2025, for the supply of Perjeta 420 mg/14 mL vials. This firm fixed-price delivery order, valued at $18,229.08, is scheduled for completion by October 20, 2025, with performance at the contractor's Park Ridge, Illinois location. The award was issued without a set-aside designation, allowing DMS Pharmaceutical Group to compete on an unrestricted basis. Perjeta is a targeted cancer therapy commonly used in oncology treatment regimens, reflecting the contractor's specialization in providing specialized pharmaceutical products to federal healthcare systems.
This delivery order is issued under DMS Pharmaceutical Group's existing Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, a single-award vehicle valued at $499,999,999 and valid through November 2026. This IDC framework enables the DLA to procure a comprehensive range of pharmaceutical products, including branded and generic prescription drugs, biologics, and medical consumables to support the medical supply requirements of military health facilities worldwide. The contractor's consistent success in securing DLA delivery orders demonstrates its established position as a critical supplier within the federal pharmaceutical supply chain, providing direct distribution of prescription drugs and specialty medications to Department of Defense healthcare sites.
Quick answers
Who was awarded contract SPE2DB25FPRR5?
SPE2DB25FPRR5 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on September 26, 2025.
How much is contract SPE2DB25FPRR5 worth?
The government has obligated $18,229 on SPE2DB25FPRR5.
Is contract SPE2DB25FPRR5 an order under another contract?
Yes. SPE2DB25FPRR5 is a delivery order under SPE2DB20D9127, an indefinite delivery contract.
Was contract SPE2DB25FPRR5 competed?
The extent of competition for SPE2DB25FPRR5 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award